All studies
Oncology · Registry + Claims · US
Petito 2020
Colorectal cancer, Pancreatic cancer
PPSuperiorityAcademia, Industry, Government2/5 disclosures
Comparisons
2
In the analysis
1
1 withheld
Target trials
2
Emulations reported
2
3 treatments
Design and methods
- Estimand
- PP
- Design hypothesis
- Superiority
- Matching / weighting
- IPTW
- Analysis method
- Cox PH
- Missing data
- LOCF, Complete case
- Covariates adjusted
- 25
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Registry + Claims
- Data sources
- 1
- Geography
- US
- Eligible sample
- 9549
- Treated
- 185
- Control
- 6150
- Emulations
- 2
- Treatments compared
- 3
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- Sanofi Pasteur
- Funding
- Declared: Public, Research Institute, NGO
- Funders
- US National Cancer Institute, Patient-Centered Outcomes Research Institute, California Department of Public Health, Centers for Disease Control and Prevention
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2020_Petito_ColorectalPancreaticCancer
- DOI
- https://doi.org/10.1001/jamanetworkopen.2020.0452
- Affiliations
- Harvard T.H. Chan School of Public Health, Brown University, Feinberg School of Medicine-Northwestern University, Massachusetts General Hospital, Harvard Medical School, National Cancer Institute, RTI Health Solutions
- Sector
- Academia, Industry, Government
- Target trials (study level)
- QUASAR
- Registration
- ISRCTN82375386